Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sunfa Cheng

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
The Journal of Clinical Endocrinology and Metabolism|May 28, 2009
Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidismClaudio Marcocci, Philippe Chanson, Dolores Shoback, et al.
Clinical Therapeutics|November 14, 2021
A Phase I, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Etelcalcetide Administered Intravenously to Chinese Patients With Chronic Kidney Disease Undergoing HemodialysisChangying Xing, Jing Chen, Li Zuo, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 13, 2019
One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidismDavid A Bushinsky, Glenn M Chertow, Sunfa Cheng, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 17, 2019
ErratumDavid A Bushinsky, Glenn M Chertow, Sunfa Cheng, et al.
European Journal of Neurology|January 5, 2021
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trialMessoud Ashina, Peter J Goadsby, Uwe Reuter, et al.
Cephalalgia : an International Journal of Headache|June 1, 2019
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraineMessoud Ashina, Peter J Goadsby, Uwe Reuter, et al.
Neurology|April 19, 2019
Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind studyRichard B Lipton, Stewart J Tepper, Uwe Reuter, et al.
Headache|June 14, 2023
Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysisStewart J Tepper, Richard B Lipton, Stephen D Silberstein, et al.
Cephalalgia : an International Journal of Headache|December 3, 2020
Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a <i>post-hoc</i> analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extensionRichard B Lipton, Stewart J Tepper, Stephen D Silberstein, et al.
The Journal of Headache and Pain|July 24, 2021
Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trialsStewart J Tepper, Messoud Ashina, Uwe Reuter, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
The Journal of Clinical Endocrinology and Metabolism|May 28, 2009
Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidismClaudio Marcocci, Philippe Chanson, Dolores Shoback, et al.
Clinical Therapeutics|November 14, 2021
A Phase I, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Etelcalcetide Administered Intravenously to Chinese Patients With Chronic Kidney Disease Undergoing HemodialysisChangying Xing, Jing Chen, Li Zuo, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 13, 2019
One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidismDavid A Bushinsky, Glenn M Chertow, Sunfa Cheng, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 17, 2019
ErratumDavid A Bushinsky, Glenn M Chertow, Sunfa Cheng, et al.
European Journal of Neurology|January 5, 2021
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trialMessoud Ashina, Peter J Goadsby, Uwe Reuter, et al.
Cephalalgia : an International Journal of Headache|June 1, 2019
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraineMessoud Ashina, Peter J Goadsby, Uwe Reuter, et al.
Neurology|April 19, 2019
Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind studyRichard B Lipton, Stewart J Tepper, Uwe Reuter, et al.
Headache|June 14, 2023
Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysisStewart J Tepper, Richard B Lipton, Stephen D Silberstein, et al.
Cephalalgia : an International Journal of Headache|December 3, 2020
Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a <i>post-hoc</i> analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extensionRichard B Lipton, Stewart J Tepper, Stephen D Silberstein, et al.
The Journal of Headache and Pain|July 24, 2021
Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trialsStewart J Tepper, Messoud Ashina, Uwe Reuter, et al.
Pageof 5